Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + SHR-A1811 + pertuzumab as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2600118900Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, trastuzumab rezetecan and pertuzumab in breast cancer, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Total Pathological Complete Response Rate (tpCR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
atezolizumabtrastuzumab rezetecanpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600118900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118900.